Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Very Strong
Momentum
Price
Strong
Earnings
Neutral
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.9824.5254
Address
Level 3 62 Lygon Street Carlton, Victoria (VIC) 3053
Description
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. Its products include b-cell peptide cancer vaccines, arginine modulators, and mimotopes. The company was founded on May 30, 1986 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.04 - 0.15
Trade Value (12mth)
AU$640,199.00
1 week
-3.51%
1 month
-3.51%
YTD
-50%
1 year
-38.2%
All time high
0.63
EPS 3 yr Growth
130.800%
EBITDA Margin
N/A
Operating Cashflow
-$30m
Free Cash Flow Return
-18.10%
ROIC
-23.00%
Interest Coverage
-1,788.10
Quick Ratio
27.20
Shares on Issue (Fully Dilluted)
6882m
HALO Sector
Healthcare
Next Company Report Date
30-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
4.67
Date | Announcements |
---|---|
12 July 24 |
Notification regarding unquoted securities - IMU
×
Notification regarding unquoted securities - IMU |
12 July 24 |
Notification of cessation of securities - IMU
×
Notification of cessation of securities - IMU |
10 July 24 |
First patient dosed in Phase 1 bile tract cancer trial
×
First patient dosed in Phase 1 bile tract cancer trial |
08 July 24 |
Application for quotation of securities - IMU
×
Application for quotation of securities - IMU |
08 July 24 |
Change of Director's Interest Notice x6
×
Change of Director's Interest Notice x6 |
04 July 24 |
Imugene Corporate Presentation
×
Imugene Corporate Presentation |
24 June 24 |
Imugene onCARlytics Doses First Patient in IV Combination
×
Imugene onCARlytics Doses First Patient in IV Combination |
30 May 24 |
Imugene Presentation to Bell Potter Conference
×
Imugene Presentation to Bell Potter Conference |
06 May 24 |
Application for quotation of securities - IMU
×
Application for quotation of securities - IMU |
30 April 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
23 April 24 |
Change of Director's Interest Notice - PH
×
Change of Director's Interest Notice - PH |
19 April 24 |
Notification regarding unquoted securities - IMU
×
Notification regarding unquoted securities - IMU |
17 April 24 |
Imugene & Kincell Bio Strategic Partnership Investor Webinar
×
Imugene & Kincell Bio Strategic Partnership Investor Webinar |
16 April 24 |
Imugene and Kincell Bio Announce Strategic Partnership
×
Imugene and Kincell Bio Announce Strategic Partnership |
15 April 24 |
Bile Tract Cancer Study Opens after MAST High Dose Clearance
×
Bile Tract Cancer Study Opens after MAST High Dose Clearance |
15 April 24 |
Notification regarding unquoted securities - IMU
×
Notification regarding unquoted securities - IMU |
15 April 24 |
Notification of cessation of securities - IMU
×
Notification of cessation of securities - IMU |
08 April 24 |
VAXINIA and HER-Vaxx featured at the AACR Annual Meeting
×
VAXINIA and HER-Vaxx featured at the AACR Annual Meeting |
04 April 24 |
Oncolytic Virotherapy CF33 Patent Granted in China
×
Oncolytic Virotherapy CF33 Patent Granted in China |
03 April 24 |
Imugene to present at 2024 Cholangiocarcinoma Conference
×
Imugene to present at 2024 Cholangiocarcinoma Conference |
02 April 24 |
Application for quotation of securities - IMU
×
Application for quotation of securities - IMU |
02 April 24 |
Cleansing Notice
×
Cleansing Notice |
11 March 24 |
Phase 1 onCARlytics Trial Advances to Combination Arm
×
Phase 1 onCARlytics Trial Advances to Combination Arm |
29 February 24 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
15 February 24 |
Phase 1 onCARlytics Trial Doses First Intravenous Patient
×
Phase 1 onCARlytics Trial Doses First Intravenous Patient |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.